ABEONA THERAPEUT. DL-01 Total Assets
ABEONA THERAPEUT. DL-01 total assets. Based on the latest financial reports, ABEONA THERAPEUT. DL-01 (PCJ) holds total assets worth €219.57 Million EUR (≈ $256.70 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ABEONA THERAPEUT. DL-01 market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of ABEONA THERAPEUT. DL-01 (2021–2025)
Total assets of ABEONA THERAPEUT. DL-01 from 2021 to 2025. This chart illustrates how ABEONA THERAPEUT. DL-01's total assets have evolved over time, based on quarterly financial data. See PCJ share price today for real-time trading data and today's change.
ABEONA THERAPEUT. DL-01 - Asset Composition Analysis
ABEONA THERAPEUT. DL-01 Total Assets Breakdown (December 2025)
ABEONA THERAPEUT. DL-01 total assets breakdown as of December 2025. ABEONA THERAPEUT. DL-01's total assets of €219.57 Million consist of 93.3% current assets and 6.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 35.7% |
| Accounts Receivable | €6.15 Million | 2.8% |
| Inventory | €5.49 Million | 2.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ABEONA THERAPEUT. DL-01's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of ABEONA THERAPEUT. DL-01 to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ABEONA THERAPEUT. DL-01's current assets represent 93.3% of total assets in 2025, an increase from 70.7% in 2021.
- Cash Position: Cash and equivalents constituted 35.7% of total assets in 2025, down from 41.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 2.8% of total assets.
ABEONA THERAPEUT. DL-01 Competitors by Total Assets
Key competitors of ABEONA THERAPEUT. DL-01 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
ABEONA THERAPEUT. DL-01 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.93 | 6.08 | 6.12 |
| Quick Ratio | 6.74 | 6.08 | 6.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €175.34 Million | €84.27 Million | €94.23 Million |
ABEONA THERAPEUT. DL-01 - Advanced Valuation Insights
This section examines the relationship between ABEONA THERAPEUT. DL-01's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.01 |
| Latest Market Cap to Assets Ratio | 1.17 |
| Asset Growth Rate (YoY) | 101.6% |
| Total Assets | €219.57 Million |
| Market Capitalization | $256.10 Million USD |
Valuation Analysis
Above Book Valuation: The market values ABEONA THERAPEUT. DL-01's assets above their book value (1.17x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: ABEONA THERAPEUT. DL-01's assets grew by 101.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ABEONA THERAPEUT. DL-01 (2021–2025)
The table below shows the annual total assets of ABEONA THERAPEUT. DL-01 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €219.57 Million ≈ $256.70 Million |
+101.57% |
| 2024-12-31 | €108.93 Million ≈ $127.35 Million |
+70.20% |
| 2023-12-31 | €64.00 Million ≈ $74.83 Million |
-0.33% |
| 2022-12-31 | €64.21 Million ≈ $75.07 Million |
-19.31% |
| 2021-12-31 | €79.59 Million ≈ $93.04 Million |
-- |
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more